Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Business Officer | September 11, 2023 | September 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Replimune Group, Inc.
Report date September 11, 2023 · Filed September 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,794 |
Reported balance
After 2023-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-11 · Exercise / conversion · Acquired 5,358 · Balance 268,794 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-11 · Sale · Disposed 5,358 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 263,736 |
Reported balance
After 2023-09-12 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-09-12 · Exercise / conversion · Acquired 300 · Balance 263,736 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-12 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-09-12 · Sale · Disposed 300 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,333 |
Reported balance
After 2023-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-11 · Exercise / conversion · Disposed 5,358 · Balance 86,333 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,033 |
Reported balance
After 2023-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-12 · Exercise / conversion · Disposed 300 · Balance 86,033 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,273 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · derivative · entry 9 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,930 Underlying: Common Stock · 29,273 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 29,273 | $43.58 | $1,275,717.34 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 29,273 | $1.01 | $29,565.73 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,273 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · derivative · entry 9 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,930 Underlying: Common Stock · 29,273 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 15, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 29,273 | $43.58 | $1,275,717.34 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 15, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 29,273 | $1.01 | $29,565.73 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · derivative · entry 8 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,203 Underlying: Common Stock · 20,000 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 20,000 | $45.02 | $900,400.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 20,000 | $1.01 | $20,200.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · derivative · entry 8 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,203 Underlying: Common Stock · 20,000 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 14, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 20,000 | $45.02 | $900,400.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 14, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 20,000 | $1.01 | $20,200.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,704 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-20-139951 · tm2039457-1_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,758 Underlying: Common Stock · 50,704 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this stock option vested on February 28, 2017 and the remainder of the shares underlying this stock option vested in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 02:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 50,704 | $1.75 | $88,732.00 |
DisclosureSEC source: 0001104659-20-139951 · tm2039457-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 02:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,590 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-20-135903 · tm2038101-5_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,691 Underlying: Common Stock · 12,590 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this stock option vested on July 26, 2018 and the remainder of the shares underlying this stock option vested or will vest, as applicable, in equal monthly installments thereafter until July 26, 2021. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 02:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 12,590 | $3.30 | $41,547.00 |
DisclosureSEC source: 0001104659-20-135903 · tm2038101-5_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 22:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-20-115710 · a4.xml · derivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,203 Underlying: Common Stock · 16,000 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying the stock option have vested and are exercisable as of the date hereof. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 22:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,000 | $35.04 | $315,360.00 |
DisclosureSEC source: 0001104659-20-115710 · a4.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,700 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 15, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.20. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 112,700 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 577,146 shares of the Issuer's common stock, 384,273 of which are exercisable as of the date hereof. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 22:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,000 | $30.15 | $211,050.00 |
DisclosureSEC source: 0001104659-20-115710 · a4.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,700 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 15, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.57. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 22:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 16,000 | $1.01 | $16,160.00 |
DisclosureSEC source: 0001104659-20-115710 · a4.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 20:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 40,127 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0000899243-20-024765 · doc4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,127 Underlying: Common Stock · 40,127 shares Expires 2030-09-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on September 4, 2020. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:13 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-20-101464 · a4.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,203 Underlying: Common Stock · 5,000 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying the stock option have vested and are exercisable as of the date hereof. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:13 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,000 | $27.05 | $135,250.00 |
DisclosureSEC source: 0001104659-20-101464 · a4.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,700 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 15, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 112,700 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 593,146 shares of the Issuer's common stock, 394,440 of which are exercisable as of the date hereof. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:13 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,000 | $1.01 | $5,050.00 |
DisclosureSEC source: 0001104659-20-101464 · a4.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 85,450 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042512 · a4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,450 Underlying: Common Stock · 85,450 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:32 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-19-075616 · a4.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,462 Underlying: Common Stock · 25,700 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted a stock option to acquire 196,162 shares of the Issuer's common stock, subject to vesting. Approximately 183,878 shares underlying the stock option have vested as of the date hereof, with the remaining shares underlying the stock option to vest in 3 approximately equal monthly installments as of the 29th of each month. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:32 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 25,700 | $1.75 | $44,975.00 |
DisclosureSEC source: 0001104659-19-075616 · a4.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:21 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 75,750 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019705 · a4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,750 Underlying: Common Stock · 75,750 shares Expires 2029-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2020, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-18-073330 · a4.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,162 Underlying: Common Stock · 87,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted a stock option to acquire 196,162 shares of the Issuer's common stock, subject to vesting. 134,846 shares underlying the stock option have vested with the remaining 61,316 shares underlying the stock option to vest in 15 equal monthly installments as of the 29th of each month. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 87,000 | $1.75 | $152,250.00 |
DisclosureSEC source: 0001104659-18-073330 · a4.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:23 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047453 · a4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-07-19 F1 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.